Ligand ID: AXI Drugbank ID: DB06626(Axitinib) Indication:Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 1ssk | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 5 / 11 | LEU A 99ALA A 97THR A 93GLY A 63ALA A 116 | 1.15A | 20.34 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 1wof | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ILE A 259LEU A -2VAL A 296GLY A 2LEU A 282 | 1.28A | 21.11 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ILE A 200LEU A 167VAL A 171LYS A 137GLU A 290 | 1.23A | 20.66 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2a5k | 3C-LIKE PEPTIDASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.30A | 20.71 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2a5k | 3C-LIKE PEPTIDASE (SARSr-CoV) | 6 / 12 | LEU A 167VAL A 171LYS A 137GLU A 290PHE A 185GLY A 195 | 1.62A | 23.95 | AZP A 307 (-3.8A)NoneNoneNoneAZP A 307 (-3.9A)None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 5 / 12 | VAL A 333ALA A 306VAL A 277VAL A 218LEU A 309 | 1.22A | 19.75 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAINREPLICASEPOLYPROTEIN 1AB,LIGHT CHAIN (SARSr-CoV) | 5 / 12 | LEU E 100VAL A 21VAL A 17LEU A 64PHE E 97 | 1.41A | 21.02 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2ajf | ACE2SPIKE PROTEIN (Homosapiens;SARSr-CoV) | 6 / 11 | LEU A 45TYR E 484LYS A 353ASN E 435ALA E 430PHE E 483 | 1.76A | 20.73 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ajf | ACE2 (Homosapiens) | 5 / 12 | LEU A 558GLU A 549VAL A 318LEU A 320PHE A 555 | 1.42A | 20.13 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ajf | SPIKE PROTEIN (SARSr-CoV) | 5 / 12 | LEU E 355VAL E 497PHE E 364LEU E 499PHE E 325 | 1.30A | 19.46 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 2alv | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.45A | 20.80 | CY6 A1145 ( 4.9A)NoneNoneNoneNone | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 2amq | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 75VAL A 91LYS A 90MET A 17ASP A 33 | 1.51A | 20.67 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2amq | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU B 67VAL B 36VAL B 18LEU B 89CYH B 38 | 1.46A | 23.21 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2c3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.29A | 20.77 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2d2d | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | LEU B 227MET B 264ASN B 203LEU B 205ALA B 206 | 1.47A | 21.11 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2dd8 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL S 496THR S 363PHE S 364GLY S 418ALA S 398 | 1.36A | 21.03 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 5 / 12 | VAL C 152ALA C 125VAL C 96VAL C 37LEU C 128 | 1.20A | 20.19 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 6 / 11 | ALA B 154MET B 85GLY B 82LEU B 81ALA B 69PHE B 70 | 1.75A | 24.20 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 6 / 12 | LEU A 124ALA A 120LEU A 114VAL A 117LEU A 174PHE A 128 | 1.78A | 22.31 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | TYR C 36PHE A 70GLY C 82LEU C 59PHE C 56 | 1.44A | 24.20 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU E 421VAL E 496PHE E 364GLY E 418ALA E 398 | 1.44A | 20.50 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU E 374VAL C 497PHE C 364LEU C 499PHE C 325 | 1.11A | 20.44 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL E 496THR E 363PHE E 364GLY E 418ALA E 398 | 1.35A | 20.88 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL E 382ALA E 384LEU E 412LEU E 421PHE E 379 | 1.39A | 18.64 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ghw | ANTI-SCFV ANTIBODY,80R (Homosapiens) | 6 / 12 | LEU D 145VAL D 236ALA D 151LEU D 179GLY D 148PHE D 215 | 1.02A | 21.53 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2ghw | ANTI-SCFV ANTIBODY,80R (Homosapiens) | 5 / 12 | LEU D 145VAL D 236ALA D 151GLY D 148PHE D 215 | 1.06A | 20.83 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2gtb | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ILE A 200LEU A 167VAL A 171LYS A 137GLU A 290 | 1.39A | 20.77 | NoneAZP A 401 (-3.7A)NoneNoneNone | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2k7x | REPLICASEPOLYPROTEIN 1AB MAINPROTEASE (SARS-COVSino1-11) | 5 / 12 | VAL A 204THR A 199GLY A 275LEU A 272ALA A 234 | 1.51A | 17.28 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2k7x | REPLICASEPOLYPROTEIN 1AB MAINPROTEASE (SARS-COVSino1-11) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.45A | 17.28 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2liz | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ILE A 286LEU A 202ALA A 206GLU A 288LEU A 268 | 1.37A | 17.96 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2ofz | NUCLEOCAPSID PROTEIN (SARS-COVTor2) | 5 / 12 | TYR A 88THR A 166LEU A 160ALA A 174PHE A 172 | 1.54A | 18.69 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 2og3 | NUCLEOCAPSID PROTEIN (SARS-COVTor2) | 5 / 12 | LEU A 122TYR A 87ALA A 126GLY A 115LEU A 114 | 1.52A | 18.45 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2op9 | REPLICASEPOLYPROTEIN 1AB(PP1AB, ORF1AB)3C-LIKE PROTEINASE(3CL-PRO, 3CLP) (SARSr-CoV) | 5 / 12 | LEU B 67VAL B 36VAL B 18LEU B 89CYH B 38 | 1.43A | 23.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2op9 | REPLICASEPOLYPROTEIN 1AB(PP1AB, ORF1AB)3C-LIKE PROTEINASE(3CL-PRO, 3CLP) (SARSr-CoV) | 5 / 11 | MET B 264ASN B 203LEU B 205ALA B 206PHE B 294 | 1.34A | 20.54 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2pwx | 3C-LIKE PROTEINASE (SARS-COVBJ01) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.30A | 21.30 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2q6g | REPLICASEPOLYPROTEIN 1AB (SARS-COVBJ01) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.35A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2q6g | REPLICASEPOLYPROTEIN 1AB (SARS-COVBJ01) | 5 / 12 | LEU B 67VAL B 36VAL B 18LEU B 89CYH B 38 | 1.45A | 22.64 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2qcy | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.35A | 20.77 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2xyq | NSP10PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ILE A 36VAL B 42ALA A 83VAL A 84GLY A 73 | 1.22A | 20.87 | NoneNoneNoneNoneSAH A1293 (-4.1A) | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 11 | THR A 191MET A 184GLY A 185ASN A 210ALA A 209 | 1.48A | 23.08 | NoneNoneNone NA A1295 (-4.3A)None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 2xyr | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 11 | THR A 191MET A 184GLY A 185ASN A 210ALA A 209 | 1.47A | 22.25 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2xyr | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | LEU A 126ALA A 168VAL A 169GLY A 165LEU A 161 | 1.46A | 21.59 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 2xyv | NSP10PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ILE A 36VAL B 42ALA A 83VAL A 84GLY A 73 | 1.23A | 18.90 | NoneNoneNoneNoneSAH A1300 (-4.1A) | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 2zu4 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.35A | 20.80 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3atw | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET B 264ASN B 203LEU B 205ALA B 206PHE B 294 | 1.27A | 20.77 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3aw0 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.46A | 22.64 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 5 / 12 | VAL S 496THR S 363PHE S 364GLY S 418ALA S 398 | 1.39A | 20.62 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 5 / 12 | LEU S 421VAL S 496PHE S 364GLY S 418ALA S 398 | 1.39A | 20.29 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 5 / 12 | LEU S 355VAL S 497PHE S 364LEU S 499PHE S 325 | 1.36A | 18.99 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3d0g | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL F 496THR F 363PHE F 364GLY F 418ALA F 398 | 1.45A | 18.43 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3d0g | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU A 440ALA A 443LEU A 584VAL A 447LEU A 595 | 1.38A | 22.11 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3d0g | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU B 236VAL B 581PHE B 588GLY B 448LEU B 450 | 1.43A | 19.47 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3d0h | ACE2SPIKE GLYCOPROTEIN (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 11 | TYR E 484LYS A 353ASN E 435ALA E 430PHE E 483 | 1.50A | 18.43 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 3d0h | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU E 421VAL E 496PHE E 364GLY E 418ALA E 398 | 1.47A | 19.56 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3d0h | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL E 496THR E 363PHE E 364GLY E 418ALA E 398 | 1.40A | 18.43 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3d0i | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL F 496THR F 363PHE F 364GLY F 418ALA F 398 | 1.48A | 18.77 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3d62 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.31A | 20.24 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3e91 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | VAL B 157LEU B 115VAL B 148LEU B 32CYH B 16 | 1.41A | 20.66 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3e91 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.41A | 20.48 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3e9s | NSP3 (SARSr-CoV) | 5 / 11 | LEU A 88THR A 11GLY A 82LEU A 81ALA A 69 | 1.44A | 23.99 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3eaj | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU B 67VAL B 36VAL B 18LEU B 89CYH B 38 | 1.46A | 22.64 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3eaj | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | LEU B 227MET B 264ASN B 203LEU B 205ALA B 206 | 1.47A | 20.48 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3ebn | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 11 | MET A 264ASN C 203LEU C 205ALA C 206PHE A 294 | 1.33A | 17.28 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3fzd | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.29A | 20.60 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU C 67VAL C 36VAL C 18LEU C 89CYH C 38 | 1.42A | 22.64 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ILE B 200LEU B 167VAL B 171ALA B 173LYS B 137 | 1.24A | 20.66 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3m3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.35A | 20.77 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3m3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.46A | 22.57 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3m3t | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.36A | 21.30 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3r24 | 2'-O-METHYLTRANSFERASENSP10 AND NSP11 (SARSr-CoV) | 5 / 12 | ILE A 36VAL B 42ALA A 83VAL A 84GLY A 73 | 1.27A | 21.17 | NoneNoneNoneNoneSAM A 302 (-4.1A) | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3sci | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL E 496THR E 363PHE E 364GLY E 418ALA E 398 | 1.42A | 19.46 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3sci | ACE2 (Homosapiens) | 5 / 12 | LEU B 236VAL B 581PHE B 588GLY B 448LEU B 450 | 1.44A | 20.13 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 3sci | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU E 355VAL E 497PHE E 364LEU E 499PHE E 325 | 1.46A | 21.15 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3scj | ACE2SPIKE GLYCOPROTEIN (Homosapiens;SARSr-CoV) | 6 / 11 | LEU B 45TYR F 484LYS B 353ASN F 435ALA F 430PHE F 483 | 1.74A | 20.73 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 3scl | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL E 496THR E 363PHE E 364GLY E 418ALA E 398 | 1.49A | 18.49 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 3scl | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU E 421VAL E 496PHE E 364GLY E 418ALA E 398 | 1.52A | 19.56 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 3sna | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.43A | 20.68 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.30A | 20.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | LEU A 167VAL A 171LYS A 137GLU A 290PHE A 185GLY A 195 | 1.67A | 22.54 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 6 / 12 | ILE A 200LEU A 167VAL A 171LYS A 137GLU A 290GLY A 195 | 1.72A | 20.70 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 4m0w | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 6 / 11 | ALA A 154MET A 85GLY A 82LEU A 81ALA A 69PHE A 70 | 1.71A | 23.05 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 4mm3 | PAPAIN-LIKEPROTEINASEUBIQUITIN (Homosapiens;SARSr-CoV) | 5 / 12 | ILE B 105LEU A 73LEU B 119GLY B 272CYH B 112 | 1.28A | 21.26 | NoneNoneNoneNoneGLZ A 76 ( 1.7A) | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 4ovz | PAPAIN-LIKEPROTEINASE (SARS-COVUrbani) | 5 / 12 | VAL A 226GLY B 272ASN B 111LEU B 163ASP B 109 | 1.47A | 23.95 | NoneNoneOCS B 112 ( 4.0A)P85 B 902 (-4.1A)None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5b6o | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.45A | 20.76 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5c5o | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | MET B 264ASN B 203LEU B 205ALA B 206PHE B 294 | 1.43A | 20.77 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ILE D 397VAL D 346ALA D 344VAL D 341LEU D 322 | 1.37A | 20.79 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.27A | 19.09 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 11 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.34A | 20.36 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.31A | 20.36 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5c8t | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ILE D 397VAL D 346ALA D 344VAL D 341LEU D 322 | 1.31A | 20.94 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.31A | 19.09 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 11 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.39A | 20.36 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5c8u | GUANINE-N7METHYLTRANSFERASENSP10 (SARSr-CoV) | 5 / 12 | ILE C 38LEU D 18GLU C 6LEU C 14GLY C 94 | 1.37A | 18.21 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ALA B 119GLY B 123ASN B 137LEU B 105ALA B 138 | 1.36A | 20.36 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5e6j | REPLICASEPOLYPROTEIN 1ABUBIQUITIN (SARSr-CoV;syntheticconstruct) | 5 / 12 | ILE A 105LEU B 73LEU A 119GLY A 272CYH A 112 | 1.31A | 22.46 | NoneNoneNoneNoneAYE B 76 ( 1.6A) | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5f22 | NSP7 (SARSr-CoV) | 5 / 12 | LEU A 22VAL A 21LEU A 76VAL A 71LEU A 61 | 1.37A | 15.41 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | ALA A 119GLY A 123ASN A 137LEU A 105ALA A 138 | 1.26A | 19.48 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 11 | ALA A 119GLY A 123ASN A 137LEU A 105ALA A 138 | 1.34A | 20.36 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | ILE C 397VAL C 346ALA C 344VAL C 341LEU C 322 | 1.31A | 22.24 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | ALA A 119GLY A 123ASN A 137LEU A 105ALA A 138 | 1.30A | 20.36 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.49A | 21.10 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.46A | 23.08 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.66A | 23.36 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 202VAL A 296PHE A 294GLY A 251LEU A 253 | 1.64A | 21.10 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.50A | 19.78 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.39A | 23.08 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.64A | 23.36 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5tl6 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 11 | LEU D 88THR D 11GLY D 82LEU D 81ALA D 69 | 1.49A | 24.21 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5tl6 | REPLICASEPOLYPROTEIN 1ABUBIQUITIN-LIKEPROTEIN ISG15 (Homosapiens;SARSr-CoV) | 5 / 12 | ILE D 105LEU C 154LEU D 119GLY D 272CYH D 112 | 1.29A | 21.26 | NoneNoneNoneNoneAYE C 157 ( 1.6A) | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5x4s | SPIKE GLYCOPROTEIN (SARSr-CoV) | 6 / 12 | TYR A 252VAL A 98ALA A 250GLY A 68ALA A 90PHE A 185 | 1.72A | 18.21 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | LEU C 421VAL C 496PHE C 364GLY C 418ALA C 398 | 1.43A | 11.65 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | VAL C 496THR C 363PHE C 364GLY C 418ALA C 398 | 1.51A | 13.12 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | ILE A 913ALA A 926LEU A1045VAL A1043LEU A 803 | 1.27A | 14.11 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5x5c | S PROTEIN (MERS-CoV) | 6 / 11 | ALA C 760THR C 741GLY C 716ASN C 719LEU C 673ALA C 671 | 1.75A | 12.28 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5x5f | S PROTEIN (MERS-CoV) | 5 / 12 | TYR C 469VAL C 396PHE C 571GLY C 572LEU C 479 | 1.43A | 11.75 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 5x5f | S PROTEIN (MERS-CoV) | 5 / 12 | TYR C 469VAL C 396PHE C 571GLY C 572LEU C 479 | 1.43A | 12.28 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU B 355VAL B 497PHE B 364LEU B 499PHE B 325 | 1.42A | 12.33 | LEU B 355 ( 0.5A)VAL B 497 ( 0.6A)PHE B 364 ( 1.3A)LEU B 499 ( 0.6A)PHE B 325 ( 1.3A) | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | TYR C 819VAL C 842ALA C 714ASN C 942ALA C 938 | 1.45A | 12.00 | TYR C 819 ( 1.3A)VAL C 842 ( 0.6A)ALA C 714 ( 0.0A)ASN C 942 ( 0.6A)ALA C 938 ( 0.0A) | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE B 979LEU B 840VAL B 718LEU B 983LEU B 948 | 1.35A | 14.30 | ILE B 979 ( 0.7A)LEU B 840 ( 0.6A)VAL B 718 ( 0.6A)LEU B 983 ( 0.6A)LEU B 948 ( 0.6A) | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU A 355VAL A 354PHE A 364LEU A 499ALA A 384 | 1.47A | 12.00 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE C 979LEU C 840VAL C 718LEU C 983LEU C 948 | 1.34A | 14.30 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6acj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU C 355VAL C 497PHE C 364LEU C 499PHE C 325 | 1.25A | 12.33 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ack | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | TYR C 436THR C 487ASN C 435ALA C 430PHE C 483 | 1.46A | 13.36 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ack | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | TYR C 598VAL C 601ASN C 304LEU C 615PHE C 578 | 1.49A | 13.36 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6crw | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU A 374VAL A 328VAL A 354GLY A 418LEU A 499 | 1.14A | 13.61 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6crw | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 11 | ALA B 350LYS B 509GLY B 418LEU B 499ALA B 384 | 1.29A | 13.03 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6crw | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU A 377VAL A 510ALA A 350GLY A 418LEU A 499 | 1.12A | 14.72 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | VAL C 510ALA C 350GLY C 418LEU C 499ALA C 384 | 1.18A | 13.03 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | VAL C 510ALA C 350GLY C 418LEU C 499ALA C 384 | 1.08A | 11.45 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6cs2 | ACE2 (Homosapiens) | 5 / 12 | LEU D 262VAL D 487LYS D 481LEU D 456GLY D 268 | 1.38A | 22.28 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | VAL B 371ALA B 393GLY B 273LEU B 252ALA B 302 | 1.36A | 18.13 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | LEU A 83VAL A 60GLY A 91LEU A 14CYH A 30 | 1.34A | 20.51 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | LEU A 83VAL A 60GLY A 91LEU A 14CYH A 30 | 1.32A | 20.68 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | VAL B 371ALA B 393GLY B 273LEU B 252ALA B 302 | 1.35A | 17.41 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.52A | 22.75 | NoneNoneDMS A 403 ( 4.9A)NoneNone | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.64A | 22.75 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.53A | 21.82 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.63A | 21.23 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.63A | 21.23 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.50A | 20.81 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171GLU A 290PHE A 185GLY A 195 | 1.61A | 22.75 | DMS A 401 ( 4.9A)NoneNoneNoneNone | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | TYR A 209VAL A 212GLY A 251ALA A 260ASP A 263 | 1.69A | 21.23 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6lzg | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL B 510THR B 376PHE B 377GLY B 431ALA B 411 | 1.32A | 18.92 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m03 | MAIN PROTEASE (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.29A | 21.82 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.51A | 20.81 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.49A | 22.75 | NoneNoneDMS A 401 ( 4.8A)NoneNone | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.52A | 21.82 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171GLU A 290PHE A 185GLY A 195 | 1.65A | 22.75 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.61A | 22.75 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.66A | 21.47 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173PHE A 185GLY A 195 | 1.75A | 21.47 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.66A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m17 | ACE2 (Homosapiens) | 5 / 12 | LEU D 558GLU D 549VAL D 318LEU D 320PHE D 555 | 1.36A | 17.19 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m17 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | ILE A 72LEU A 75VAL A 315GLY A 250LEU A 254 | 1.33A | 18.91 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m18 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | LEU A 127PHE A 473GLY A 470LEU A 201ALA A 204 | 1.52A | 17.30 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m18 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 11 | ALA A 273GLY A 490LEU A 494ALA A 498PHE A 499 | 1.50A | 15.99 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m1d | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | PHE C 433MET C 432GLY C 428ASN C 54PHE C 279 | 1.43A | 15.99 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m1d | ACE2 (Homosapiens) | 6 / 12 | ILE D 544LEU D 560ALA D 569LEU D 529VAL D 573GLY D 395 | 1.66A | 18.38 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU D 167VAL D 171GLU D 290PHE D 185GLY D 195 | 1.66A | 22.57 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.65A | 22.57 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 268VAL C 247VAL C 261LEU C 242PHE C 230 | 1.49A | 22.57 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ILE A 136ALA A 7LYS A 5GLU A 290GLY A 124 | 1.58A | 20.60 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 67VAL C 36VAL C 18LEU C 89CYH C 38 | 1.49A | 22.57 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL D 157LEU D 115VAL D 148LEU D 32CYH D 16 | 1.47A | 20.60 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU C 227MET C 264ASN C 203LEU C 205ALA C 206 | 1.47A | 21.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | MET C 264ASN C 203LEU C 205ALA C 206PHE C 294 | 1.35A | 21.82 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.72A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL D 77VAL D 35LEU D 87CYH D 38PHE D 66 | 1.61A | 22.57 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL B 157LEU B 115VAL B 148LEU B 32CYH B 16 | 1.49A | 20.60 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | ILE D 200ALA D 7LYS D 5GLU D 288GLY D 149 | 1.54A | 20.60 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 205VAL B 202PHE B 230LEU B 227ASP B 245 | 1.73A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL B 77VAL B 35LEU B 87CYH B 38PHE B 66 | 1.63A | 22.57 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 205VAL B 202PHE B 230LEU B 227ASP B 245 | 1.73A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 67VAL B 36VAL B 18LEU B 89CYH B 38 | 1.47A | 22.57 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 205VAL C 202PHE C 230LEU C 227ASP C 245 | 1.53A | 21.47 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL C 157LEU C 115VAL C 148LEU C 32CYH C 16 | 1.48A | 20.60 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.72A | 21.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.49A | 21.82 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.73A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU D 268VAL D 247VAL D 261LEU D 242PHE D 230 | 1.60A | 22.57 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.66A | 21.82 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.49A | 22.57 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 268VAL A 247VAL A 261LEU A 242PHE A 230 | 1.60A | 22.57 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.48A | 20.60 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 205VAL C 202PHE C 230LEU C 227ASP C 245 | 1.53A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU D 67VAL D 36VAL D 18LEU D 89CYH D 38 | 1.65A | 22.57 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL C 77VAL C 35LEU C 87CYH C 38PHE C 66 | 1.65A | 22.57 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU B 227MET B 264ASN B 203LEU B 205ALA B 206 | 1.51A | 21.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | GLY B 170ASN B 133LEU B 167ALA B 194PHE B 134 | 1.68A | 21.82 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL C 202VAL C 296PHE C 294GLY C 251LEU C 253 | 1.65A | 22.57 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL C 125ALA A 7GLY A 11LEU A 115PHE C 8 | 1.68A | 21.82 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY B 170ASN B 133LEU B 167ALA B 194PHE B 134 | 1.73A | 21.82 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.70A | 21.47 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.49A | 21.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.79A | 21.82 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.72A | 21.47 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.59A | 21.47 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 73ALA A 70VAL A 36VAL A 68GLY A 15 | 1.58A | 22.57 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.70A | 21.47 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.48A | 20.60 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.50A | 22.57 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m3m | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 122TYR C 87ALA C 126GLY C 115LEU C 114 | 1.52A | 20.00 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 388TYR A 674VAL A 398ALA A 399GLY A 671 | 1.66A | 14.73 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.79A | 14.85 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.50A | 15.92 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 345 | 1.27A | 19.37 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 388TYR A 674VAL A 398ALA A 399GLY A 671 | 1.67A | 14.73 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 95VAL C 16VAL C 12LEU C 59PHE D 92 | 1.47A | 20.25 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.63A | 15.92 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.64A | 15.92 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 674VAL A 667PHE A 504GLY A 671ALA A 449 | 1.45A | 14.73 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 688THR A 687LEU A 638ALA A 634PHE A 694 | 1.61A | 14.85 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 17VAL C 16LEU C 71VAL C 66LEU C 56 | 1.41A | 15.46 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.67A | 15.92 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 757LEU A 469VAL A 472VAL A 637LEU A 630 | 1.57A | 17.59 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 838ALA A 423GLU A 431VAL A 424PHE A 419 | 1.54A | 15.30 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 688THR A 687LEU A 638ALA A 634PHE A 694 | 1.68A | 14.85 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | LEU A 758ALA A 688THR A 687ALA A 634PHE A 694 | 1.77A | 14.85 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | LEU A 186ALA A 250ASN A 314LEU A 316PHE A 321 | 1.79A | 14.85 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 351ALA A 656VAL A 535PHE A 652GLY A 352 | 1.63A | 15.30 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 423VAL A 880PHE A 429GLY A 839PHE A 859 | 1.56A | 15.30 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 11 | LEU B 117ALA A 383ASN B 105LEU B 103ALA B 102 | 1.75A | 23.44 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.65A | 16.00 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.56A | 15.92 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 388TYR A 674VAL A 398ALA A 399GLY A 670 | 1.69A | 14.73 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.53A | 15.92 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 673TYR A 674VAL A 667PHE A 504GLY A 671 | 1.52A | 14.73 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 327 | 1.42A | 19.37 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 11 | LEU B 98ALA A 379LEU B 91ALA A 375PHE A 504 | 1.76A | 23.44 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE A 979LEU A 840VAL A 718LEU A 983LEU A 948 | 1.41A | 14.05 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAIN (Homosapiens) | 6 / 12 | TYR H 208VAL H 225ALA H 139GLY H 204LEU H 203ALA H 150 | 1.59A | 19.80 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAIN (Homosapiens) | 6 / 12 | TYR H 208VAL H 225ALA H 139GLY H 204LEU H 203ALA H 150 | 1.57A | 20.57 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAINS230 ANTIGEN-BINDING(FAB) FRAGMENT,LIGHT CHAIN (Homosapiens) | 5 / 12 | VAL H 225ALA H 139LEU L 140GLY H 204LEU H 203 | 1.31A | 19.88 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6nur | NSP7NSP8 (SARSr-CoV) | 5 / 12 | LEU D 95VAL C 16VAL C 12LEU C 59PHE D 92 | 1.33A | 19.49 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6nur | NSP12 (SARSr-CoV) | 5 / 12 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.41A | 14.88 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6nur | NSP12NSP7 (SARSr-CoV) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.43A | 18.34 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6nur | NSP12 (SARSr-CoV) | 5 / 11 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.43A | 14.88 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6nur | NSP12 (SARSr-CoV) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.41A | 15.38 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6nur | NSP12 (SARSr-CoV) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.45A | 14.33 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 368VAL B 511PHE B 377LEU B 513PHE B 338 | 1.26A | 13.68 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL C 524ALA C 363GLY C 431LEU C 513ALA C 397 | 1.45A | 11.88 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL C 524ALA C 363GLY C 431LEU C 513ALA C 397 | 1.42A | 11.53 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE C 997LEU C 858VAL C 736LEU C1001LEU C 966 | 1.41A | 14.41 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.43A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.72A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.52A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | TYR B 113VAL B 147PHE B 168LEU B 153ALA B 124 | 1.66A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | ILE A 137LEU A 123ALA A 154LEU A 160VAL A 155 | 1.55A | NoneNoneNoneNoneSO4 A 203 (-4.0A) | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.46A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | ILE B 137LEU B 123ALA B 154LEU B 160VAL B 155 | 1.46A | NoneNoneNoneSO4 B 204 (-4.7A)SO4 B 204 (-3.7A) | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | ALA B 27LYS B 28ASN B 54LEU B 53ALA B 52 | 1.73A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.71A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.43A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 75VAL B 96ALA B 39VAL B 36LEU B 93 | 1.60A | SO4 B 201 ( 4.4A)NoneNoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 49ALA B 38PHE B 132GLY B 130PHE B 156 | 1.79A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.48A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.60A | SO4 A 201 (-4.1A)NoneNoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 510THR A 376PHE A 377GLY A 431ALA A 411 | 1.51A | 12.76 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 981ALA C 989ASN C 969LEU C 996ALA C 972 | 1.33A | 11.48 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | TYR C 266VAL C 62PHE C 92LEU C 189PHE C 32 | 1.45A | 12.76 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6vyo | NUCLEOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 121TYR C 86ALA C 125GLY C 114LEU C 113 | 1.51A | 19.03 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w01 | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE B 270LEU B 73VAL B 70ALA B 95GLY B 77 | 1.27A | 24.88 | NoneNoneNoneNonePEG B 411 ( 3.5A) | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w02 | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.40A | 19.59 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w02 | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.49A | 23.97 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w02 | NSP3 (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.41A | 21.45 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | ALA C 435VAL C 512VAL C 433PHE C 374PHE C 347 | 1.80A | 19.80 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | VAL H 211ALA H 125GLY H 190LEU H 189ALA H 136 | 1.68A | 20.07 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | VAL H 211ALA H 125GLY H 190LEU H 189ALA H 136 | 1.64A | 21.24 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | TYR H 194VAL H 211GLY H 190LEU H 189ALA H 136 | 1.37A | 21.24 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | VAL C 510THR C 376PHE C 377GLY C 431ALA C 411 | 1.45A | 19.41 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w41 | CR3022 FAB HEAVYCHAINCR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 12 | LEU H 138VAL H 211ALA H 125GLU L 123PHE L 118 | 1.73A | 17.68 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | TYR H 194VAL H 211GLY H 190LEU H 189ALA H 136 | 1.45A | 21.24 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w41 | CR3022 FAB HEAVYCHAINCR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 12 | VAL H 211ALA H 125LEU L 135GLY H 190LEU H 189 | 1.57A | 16.91 | None | ||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 5 / 12 | TYR H 194VAL H 211GLY H 190LEU H 189ALA H 136 | 1.46A | 20.07 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w4b | NSP9 (SARS-CoV-2) | 5 / 11 | LEU B 49TYR B 90ALA B 29GLY B 18PHE B 91 | 1.25A | 22.29 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.71A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A6925LEU A7052VAL A6859LEU A6959GLY A6890 | 1.58A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w61 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.56A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | LEU B4298ALA A6843LEU A7037VAL A6995GLY A6837 | 1.68A | 18.68 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w61 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.69A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7027LEU A7037ALA A6997VAL A6992GLY A6829 | 1.76A | 17.61 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6848ALA A6966LEU A6959VAL A6965LEU A6857 | 1.55A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A6969LEU A6855LEU A6978VAL A6965LEU A6848 | 1.80A | 17.61 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w61 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | ILE A6926LEU B4298VAL A6842ALA A6843CYH A6849 | 1.60A | 17.61 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 268VAL A 247VAL A 261LEU A 242PHE A 230 | 1.61A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.50A | 21.82 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.76A | 21.82 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.68A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.51A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.46A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.69A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ALA B 39VAL B 36VAL B 95GLY B 51CYH B 92 | 1.74A | 20.78 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 49ALA B 38LEU B 123VAL B 36LEU B 126 | 1.67A | 19.77 | NoneMES B 201 ( 3.4A)NoneNoneNone | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 75VAL B 96ALA B 39VAL B 36LEU B 93 | 1.60A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ALA A 39VAL A 36VAL A 95GLY A 51CYH A 92 | 1.76A | 20.78 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 93VAL A 82GLY A 79ASN A 72LEU A 75 | 1.79A | 25.42 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 11 | LEU B 93ALA B 39GLY B 79ASN B 72LEU B 75 | 1.63A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.39A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.63A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.46A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.43A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.39A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ILE A 18ALA A 134LEU A 164GLY A 97LEU A 127 | 1.69A | 19.77 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.68A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.64A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.79A | 25.42 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.57A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.44A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.67A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ILE B 18ALA B 134LEU B 164GLY B 97LEU B 127 | 1.69A | 19.77 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 36LEU B 109LEU B 153CYH B 143 | 1.62A | 19.77 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ALA B 38LEU B 122GLY B 51LEU B 53CYH B 92 | 1.78A | 19.77 | MES B 201 ( 3.4A)NoneNoneNoneNone | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 93VAL B 82GLY B 79ASN B 72LEU B 75 | 1.73A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.72A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | ILE B 137LEU B 123ALA B 154LEU B 160VAL B 155 | 1.61A | 19.77 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.52A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 93VAL B 82GLY B 79ASN B 72LEU B 75 | 1.68A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | LEU D4298ALA C6843LEU C7037VAL C6995GLY C6837 | 1.70A | 17.82 | NoneNoneNoneNoneFMT D4404 ( 3.7A) | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.72A | 19.51 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | LEU B4298ALA A6843LEU A7037VAL A6995PHE A7043 | 1.78A | 17.82 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | ILE A6926LEU B4298VAL A6842ALA A6843CYH A6849 | 1.60A | 16.32 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | ILE C6926LEU D4298VAL C6842ALA C6843CYH C6849 | 1.60A | 16.32 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6848ALA A6966LEU A6959VAL A6965LEU A6857 | 1.54A | 16.32 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.48A | 17.23 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C6969LEU C6855LEU C6978VAL C6965LEU C6848 | 1.76A | 16.32 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | LEU B4298ALA A6843LEU A7037VAL A6995GLY A6837 | 1.71A | 17.82 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A6969LEU A6855LEU A6978VAL A6965LEU A6848 | 1.77A | 16.32 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.61A | 17.23 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU D4284GLY D4362LEU D4328ALA D4276ASP D4275 | 1.59A | 17.23 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7027LEU A7037ALA A6997VAL A6992GLY A6829 | 1.75A | 16.32 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU D4284GLY D4362LEU D4328ALA D4276ASP D4275 | 1.46A | 17.23 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6848ALA C6966LEU C6959VAL C6965LEU C6857 | 1.54A | 16.32 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7004ALA C6990MET C7022GLY C7019ASN C6941 | 1.70A | 19.51 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 11 | LEU A6848ALA A6966LYS A6968LEU A6883ALA A6870 | 1.76A | 20.00 | NoneNoneFMT A7104 ( 3.7A)NoneNone | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA B 153GLY B 81LEU B 80ALA B 68PHE B 69 | 1.63A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ILE C 300LEU C 117ALA C 116VAL C 165GLY C 287 | 1.55A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA A 153GLY A 81LEU A 80ALA A 68PHE A 69 | 1.72A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 87THR A 10GLY A 81LEU A 80ALA A 68 | 1.57A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA C 153MET C 84GLY C 81LEU C 80PHE C 69 | 1.63A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU C 87THR C 10GLY C 81LEU C 80ALA C 68 | 1.59A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA B 86THR B 90MET B 84GLY B 81PHE B 147 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ILE B 300LEU B 117ALA B 116VAL B 165GLY B 287 | 1.45A | NoneNoneNoneNone CL B 502 (-3.6A) | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ILE A 300LEU A 117ALA A 116VAL A 165GLY A 287 | 1.53A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU B 132TYR B 136ALA B 176LYS B 126LEU B 120 | 1.70A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA A 86THR A 90MET A 84GLY A 81PHE A 147 | 1.71A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 132TYR A 136ALA A 176LYS A 126MET A 169 | 1.69A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA B 153MET B 84GLY B 81LEU B 80PHE B 69 | 1.66A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 132TYR A 136ALA A 176LYS A 126LEU A 120 | 1.75A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA C 86THR C 90MET C 84GLY C 81PHE C 147 | 1.79A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA C 153GLY C 81LEU C 80ALA C 68PHE C 69 | 1.58A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU B 132TYR B 136ALA B 176LYS B 126MET B 169 | 1.72A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | LEU B 150ALA B 131LEU B 80ALA B 68PHE B 69 | 1.72A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 12 | VAL A 41ALA A 43PHE A 90LEU A 69ALA A 16 | 1.72A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 12 | VAL A 41ALA A 43PHE A 90LEU A 69ALA A 54 | 1.78A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 12 | VAL A 41ALA A 43PHE A 90LEU A 69ALA A 16 | 1.74A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 5 / 11 | LEU A 48TYR A 89ALA A 28GLY A 17PHE A 90 | 1.23A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.74A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.65A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.48A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.60A | NoneNoneMES A 201 ( 4.7A)NoneNone | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.67A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.69A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | TYR A 113VAL A 147PHE A 168LEU A 153ALA A 124 | 1.65A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.64A | NoneMES A 201 ( 4.7A)NoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | ALA A 27LYS A 28ASN A 54LEU A 53ALA A 52 | 1.77A | NoneNoneNoneNoneMES A 202 (-4.4A) | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wcf | NSP3 (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.39A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.38A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.58A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wen | NSP3 (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.36A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.72A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.66A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.49A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.37A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.50A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 357VAL A 355ALA A 328VAL A 240LEU A 331 | 1.35A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | ALA A 231LYS A 232ASN A 258LEU A 257ALA A 256 | 1.75A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 327VAL A 240LEU A 313LEU A 357CYH A 347 | 1.60A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wey | NSP3 (SARS-CoV-2) | 5 / 11 | LEU A 297ALA A 243GLY A 283ASN A 276LEU A 279 | 1.63A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wey | NSP3 (SARS-CoV-2) | 6 / 12 | LEU A 357VAL A 355ALA A 328VAL A 299VAL A 240LEU A 331 | 1.35A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 327VAL A 239ALA A 231ASN A 258ALA A 260 | 1.73A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 357VAL A 355ALA A 328LEU A 331ALA A 316 | 1.49A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 95VAL A 16VAL A 12LEU A 59PHE B 92 | 1.36A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS A 2MET A 52ASN B 104LEU B 103ASP B 99 | 1.66A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wiq | NSP7 (SARS-CoV-2) | 5 / 12 | LEU A 17VAL A 16LEU A 71VAL A 66LEU A 56 | 1.34A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS A 2MET A 52ASN B 104LEU B 103ASP B 99 | 1.71A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | VAL B 270ALA B 264THR B 296ALA A 311PHE A 315 | 1.79A | NoneNoneNone CL B 401 ( 3.7A)None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 270ALA E 264THR E 296ALA F 311PHE F 315 | 1.79A | NoneNoneNone CL E 401 ( 4.0A)None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | VAL C 270ALA C 264THR C 296ALA D 311PHE D 315 | 1.75A | NoneNoneNone CL C 401 ( 3.8A)None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | VAL D 270ALA D 264THR D 296ALA C 311PHE C 315 | 1.78A | NoneNone CL D 401 ( 4.6A) CL D 401 ( 4.1A)None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | ALA A 264LYS A 266THR A 296GLY A 287LEU A 291 | 1.71A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 270ALA A 264THR A 296ALA B 311PHE B 315 | 1.79A | NoneNoneNone CL A 401 ( 3.7A)None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wjt | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.61A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.71A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wjt | NSP10 (SARS-CoV-2) | 5 / 12 | LEU D4284GLY D4362LEU D4328ALA D4276ASP D4275 | 1.50A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6848ALA A6966LEU A6959VAL A6965LEU A6857 | 1.53A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wjt | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.49A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C6848ALA C6966LEU C6959VAL C6965LEU C6857 | 1.54A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C7004ALA C6990MET C7022GLY C7019ASN C6941 | 1.65A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 64TYR B 87GLY B 71LEU B 161ALA B 173 | 1.66A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 121TYR B 86ALA B 125GLY B 114LEU B 113 | 1.53A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | TYR D 87THR D 165LEU D 159ALA D 173PHE D 171 | 1.71A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | TYR A 87THR A 165LEU A 159ALA A 173PHE A 171 | 1.68A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 64TYR C 87GLY C 71LEU C 161ALA C 173 | 1.67A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU D 64TYR D 87GLY D 71LEU D 161ALA D 173 | 1.74A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 64TYR C 87GLY C 71LEU C 161ALA C 173 | 1.53A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 121TYR B 86ALA B 125GLY B 114LEU B 113 | 1.55A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | TYR B 87THR B 165LEU B 159ALA B 173PHE B 171 | 1.74A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 121TYR A 86ALA A 125GLY A 114LEU A 113 | 1.49A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 121TYR A 86ALA A 125GLY A 114LEU A 113 | 1.52A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 64TYR A 87GLY A 71LEU A 161ALA A 173 | 1.61A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | TYR C 87THR C 165LEU C 159ALA C 173PHE C 171 | 1.69A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU D 64TYR D 87GLY D 71LEU D 161ALA D 173 | 1.58A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | THR B 54PHE B 110GLY B 71LEU B 161ALA B 173 | 1.49A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 64TYR B 87GLY B 71LEU B 161ALA B 173 | 1.51A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | THR D 54PHE D 110GLY D 71LEU D 161ALA D 173 | 1.56A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 121TYR C 86ALA C 125GLY C 114LEU C 113 | 1.52A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | THR A 54PHE A 110GLY A 71LEU A 161ALA A 173 | 1.56A | MES B 201 (-4.7A)NoneNoneNoneNone | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 121TYR C 86ALA C 125GLY C 114LEU C 113 | 1.50A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkq | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.59A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkq | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.47A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.72A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkq | NSP10 (SARS-CoV-2) | 5 / 12 | LEU D4284GLY D4362LEU D4328ALA D4276ASP D4275 | 1.47A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7004ALA C6990MET C7022GLY C7019ASN C6941 | 1.69A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6848ALA A6966LEU A6959VAL A6965LEU A6857 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6848ALA C6966LEU C6959VAL C6965LEU C6857 | 1.54A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | THR A 34ASN A 5LEU A 3ALA A 7PHE A 8 | 1.64A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | LEU A 215VAL A 237PHE A 204LEU A 300PHE A 222 | 1.60A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | THR B 34ASN B 5LEU B 3ALA B 7PHE B 8 | 1.61A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE A 270LEU A 73VAL A 70ALA A 95GLY A 77 | 1.31A | NoneNoneEDO A 408 (-4.0A)NoneEDO A 406 ( 3.9A) | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | THR A 34ASN A 5LEU A 3ALA A 7PHE A 8 | 1.67A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | LEU A 300THR A 196GLY A 254ASN A 200LEU A 252 | 1.69A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | THR B 34ASN B 5LEU B 3ALA B 7PHE B 8 | 1.64A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ILE B 270LEU B 73VAL B 70ALA B 95GLY B 77 | 1.25A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | LEU B 215VAL B 237PHE B 204LEU B 300PHE B 222 | 1.59A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | LEU B 300THR B 196GLY B 254ASN B 200LEU B 252 | 1.73A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173PHE A 185GLY A 195 | 1.69A | U5G A 401 (-3.9A)NoneNoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.50A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.60A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.51A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173PHE A 185GLY A 195 | 1.70A | U5G A 401 (-3.9A)NoneNoneNoneNone | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171GLU A 290PHE A 185GLY A 195 | 1.64A | U5G A 401 (-3.9A)NoneNoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | ILE A 200ALA A 7LYS A 5GLU A 288GLY A 149 | 1.50A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.63A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.50A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.59A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.72A | NoneNoneU5G A 401 (-3.9A)NoneNone | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 75VAL D 96ALA D 39VAL D 36LEU D 93 | 1.59A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.58A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.45A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU B 93ALA B 39GLY B 79ASN B 72LEU B 75 | 1.65A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 6 / 12 | LEU C 153VAL C 151ALA C 124VAL C 95VAL C 36LEU C 127 | 1.46A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.48A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU D 93ALA D 39GLY D 79ASN D 72LEU D 75 | 1.66A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.69A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124LEU D 127ALA D 112 | 1.54A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 36LEU D 109LEU D 153CYH D 143 | 1.56A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.63A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124VAL C 36LEU C 127 | 1.45A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 75VAL C 96ALA C 39VAL C 36LEU C 93 | 1.61A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.50A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.46A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.72A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE B 106LEU A 75VAL A 96GLU A 104GLY A 73 | 1.56A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.67A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.49A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 39GLU A 104VAL A 41GLY A 46 | 1.47A | NoneNoneNoneNoneAPR A 201 (-3.9A) | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124VAL D 36LEU D 127 | 1.48A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 6 / 12 | LEU D 153VAL D 151ALA D 124VAL D 95VAL D 36LEU D 127 | 1.48A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 35ALA D 27ASN D 54ALA D 56 | 1.61A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.66A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU C 93ALA C 39GLY C 79ASN C 72LEU C 75 | 1.64A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 36LEU B 109LEU B 153CYH B 143 | 1.56A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.52A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.55A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.57A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124LEU D 127ALA D 112 | 1.55A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 39GLU A 104VAL A 41GLY A 47 | 1.58A | NoneNoneNoneNoneAPR A 201 (-4.1A) | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 36LEU C 109LEU C 153CYH C 143 | 1.55A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6848ALA A6966LEU A6959VAL A6965LEU A6857 | 1.56A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7004ALA A6990MET A7022GLY A7019ASN A6941 | 1.61A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wq3 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.48A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wq3 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | ILE A6926LEU B4298VAL A6842ALA A6843CYH A6849 | 1.60A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wq3 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4284GLY B4362LEU B4328ALA B4276ASP B4275 | 1.61A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ALA C 48MET C 52ASN D 104LEU D 103ASP D 99 | 1.74A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 95VAL A 16VAL A 12LEU A 59PHE B 92 | 1.40A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS A 2MET A 52ASN B 104LEU B 103ASP B 99 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL B 83ALA B 86MET C 3ALA C 42ASP C 38 | 1.72A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 95VAL C 16VAL C 12LEU C 59PHE D 92 | 1.40A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.72A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.67A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 268VAL A 247VAL A 261LEU A 242PHE A 230 | 1.64A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.53A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.38A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | GLY A 170ASN A 133LEU A 167ALA A 194PHE A 134 | 1.78A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.48A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.67A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.57A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173LYS A 137ASP A 197 | 1.69A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.54A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | ALA A 153GLY A 81LEU A 80ALA A 68PHE A 69 | 1.60A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | TYR A 83THR A 10GLY A 81LEU A 80ALA A 68 | 1.66A | None CL A 506 (-4.0A)NoneNoneNone | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | LEU A 87THR A 10GLY A 81LEU A 80ALA A 68 | 1.49A | None CL A 506 (-4.0A)NoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | ILE A 300LEU A 117ALA A 116VAL A 165GLY A 287 | 1.49A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | ALA A 86THR A 90MET A 84GLY A 81PHE A 147 | 1.63A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6xez | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.49A | 18.94 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 202VAL A 296PHE A 294GLY A 251LEU A 253 | 1.66A | 21.10 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.44A | 22.81 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 250ALA A 206VAL A 297VAL A 296GLY A 251 | 1.79A | 21.10 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.50A | 19.78 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | TYR A 126ALA A 7LYS A 5PHE A 150ALA A 129 | 1.58A | 23.08 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.70A | 21.10 | None | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE A 200ALA A 7LYS A 5GLU A 288GLY A 149 | 1.50A | 19.78 | None | ||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.64A | 23.08 | None | ||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.62A | 23.08 | None | ||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.37A | 22.81 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.48A | 21.10 | DMS A 402 ( 4.8A)NoneNoneNoneNone | ||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 282ALA A 211LEU A 250GLY A 2PHE A 291 | 1.69A | 19.78 | None | ||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | LEU D 95VAL C 16VAL C 12LEU C 59PHE D 92 | 1.44A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | LEU B 95VAL A 16VAL A 12LEU A 59PHE B 92 | 1.40A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.74A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 11 | LYS C 2THR C 9MET C 52ASN D 104LEU D 103 | 1.78A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yi3 | NUCLEOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 16TYR A 47ALA A 133ASN A 35LEU A 121 | 1.74A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR B 198VAL B 215GLY B 194LEU B 193ALA B 140 | 1.51A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR B 198VAL B 215GLY B 194LEU B 193ALA B 140 | 1.44A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 510THR E 376PHE E 377GLY E 431ALA E 411 | 1.36A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 11 | TYR H 32THR H 0GLY H 98ASN H 77LEU H 4 | 1.69A | NoneMLI B 303 (-4.8A)NoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | VAL H 215ALA H 129GLY H 194LEU H 193ALA H 140 | 1.79A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 510THR A 376PHE A 377GLY A 431ALA A 411 | 1.34A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | LEU B 145VAL B 125VAL B 156VAL B 154GLY B 143 | 1.66A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR H 198VAL H 215GLY H 194LEU H 193ALA H 140 | 1.45A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR B 198VAL B 215GLY B 194LEU B 193ALA B 140 | 1.50A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR H 198VAL H 215GLY H 194LEU H 193ALA H 140 | 1.51A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 11 | TYR B 32THR B 0GLY B 98ASN B 77LEU B 4 | 1.67A | NoneMLI B 303 (-4.2A)NoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR H 32THR H 0GLY H 98ASN H 77LEU H 4 | 1.75A | NoneMLI B 303 (-4.8A)NoneNoneNone | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR B 32THR B 0GLY B 98ASN B 77LEU B 4 | 1.72A | NoneMLI B 303 (-4.2A)NoneNoneNone | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR H 198ALA H 129GLY H 194LEU H 193ALA H 140 | 1.63A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | HEAVY CHAIN (Homosapiens) | 5 / 12 | TYR H 198VAL H 215GLY H 194LEU H 193ALA H 140 | 1.52A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 510THR E 376PHE E 377GLY E 431ALA E 411 | 1.29A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU E 513VAL E 511ALA E 397ASN E 343ALA E 344 | 1.73A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 510ALA E 435THR E 376PHE E 377ALA E 411 | 1.68A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 524ALA E 363GLY E 431LEU E 513ALA E 397 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE A 136ALA A 7LYS A 5GLU A 290GLY A 124 | 1.57A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.59A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.61A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.47A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE A 200LEU A 167VAL A 171LYS A 137GLU A 290 | 1.36A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.51A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.50A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 11 | TYR H 32THR H 0GLY H 98ASN H 77LEU H 4 | 1.70A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR B 198VAL B 215GLY B 194LEU B 193ALA B 140 | 1.50A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | VAL H 215ALA H 129GLY H 194LEU H 193ALA H 140 | 1.79A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR B 32THR B 0GLY B 98ASN B 77LEU B 4 | 1.74A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR H 198VAL H 215GLY H 194LEU H 193ALA H 140 | 1.51A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 510THR E 376PHE E 377GLY E 431ALA E 411 | 1.36A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR H 198VAL H 215GLY H 194LEU H 193ALA H 140 | 1.45A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR H 32THR H 0GLY H 98ASN H 77LEU H 4 | 1.76A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 510THR A 376PHE A 377GLY A 431ALA A 411 | 1.35A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | TYR B 198VAL B 215GLY B 194LEU B 193ALA B 140 | 1.44A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 12 | VAL B 215ALA B 129GLY B 194LEU B 193ALA B 140 | 1.79A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yor | IGG H CHAIN (Homosapiens) | 5 / 11 | TYR B 32THR B 0GLY B 98ASN B 77LEU B 4 | 1.69A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.65A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 73ALA A 70VAL A 36VAL A 68GLY A 15 | 1.61A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.64A | NonePEG A 405 (-4.1A)NoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.48A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.65A | NonePEG A 405 (-4.1A)NoneNoneNone | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.43A | NonePEG A 405 ( 4.9A)NoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | ILE A 136ALA A 7LYS A 5GLU A 290GLY A 124 | 1.51A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.53A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.47A | NoneNonePEG A 405 ( 4.9A)NoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.57A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 35ALA D 27ASN D 54ALA D 56 | 1.74A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 75VAL E 96ALA E 39VAL E 36LEU E 93 | 1.56A | EPE E 203 (-3.6A)NoneNoneNoneNone | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124VAL E 36LEU E 127 | 1.36A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU C 93ALA C 39GLY C 79ASN C 72LEU C 75 | 1.60A | NoneNoneEPE C 202 (-3.4A)EPE C 202 (-3.5A)EPE C 202 (-3.4A) | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU C 153VAL C 151ALA C 124VAL C 95VAL C 36LEU C 127 | 1.39A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.52A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 35ALA D 27ASN D 54ALA D 56 | 1.69A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.40A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124LEU D 127ALA D 112 | 1.49A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 36LEU B 109LEU B 153CYH B 143 | 1.59A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.54A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | ALA D 38PHE D 132GLY D 47ASN C 58ASP D 22 | 1.59A | EDO D 205 (-3.5A)EDO D 205 ( 3.6A)EDO D 206 (-4.5A)EDO D 209 (-4.6A)EDO D 209 ( 3.2A) | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.46A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124VAL C 36LEU C 127 | 1.38A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124VAL D 36LEU D 127 | 1.40A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124LEU E 127ALA E 112 | 1.45A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 36LEU C 109LEU C 153CYH C 143 | 1.56A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU D 53ALA D 27LYS D 28ASN C 87ALA D 21 | 1.62A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 93VAL A 82GLY A 79ASN A 72LEU A 75 | 1.72A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.41A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU D 153VAL D 151ALA D 124VAL D 95VAL D 36LEU D 127 | 1.39A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124LEU E 127ALA E 112 | 1.46A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.67A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU B 93ALA B 39GLY B 79ASN B 72LEU B 75 | 1.61A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 75VAL B 96ALA B 39VAL B 36LEU B 93 | 1.57A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU D 93ALA D 39GLY D 79ASN D 72LEU D 75 | 1.62A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 123VAL E 35ALA E 27ASN E 54ALA E 56 | 1.69A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 93VAL E 82GLY E 79ASN E 72LEU E 75 | 1.72A | NoneNoneEPE E 203 (-3.3A)NoneEPE E 203 (-3.6A) | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.72A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU E 153VAL E 151ALA E 124VAL E 95VAL E 36LEU E 127 | 1.38A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.71A | NoneNoneEPE C 202 (-3.4A)EPE C 202 (-3.5A)EPE C 202 (-3.4A) | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.43A | NoneNoneNoneNoneNoneEDO A 202 ( 4.8A) | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.63A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.51A | NoneNoneNoneEDO A 202 ( 4.8A)None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.47A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.43A | NoneNoneNoneNoneEDO A 202 ( 4.8A) | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 36LEU D 109LEU D 153CYH D 143 | 1.57A | NoneNoneEDO D 204 ( 4.5A)NoneNone | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU E 93ALA E 39GLY E 79ASN E 72LEU E 75 | 1.61A | NoneNoneEPE E 203 (-3.3A)NoneEPE E 203 (-3.6A) | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 93VAL A 82GLY A 79ASN A 72LEU A 75 | 1.75A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.65A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 123VAL E 35ALA E 27ASN E 54ALA E 56 | 1.64A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.70A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124VAL E 36LEU E 127 | 1.42A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU E 93ALA E 39GLY E 79ASN E 72LEU E 75 | 1.61A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 36LEU D 109LEU D 153CYH D 143 | 1.53A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 123VAL E 35ALA E 27ASN E 54ALA E 56 | 1.71A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.68A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU D 53ALA D 27LYS D 28ASN C 87ALA D 21 | 1.49A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU B 93ALA B 39GLY B 79ASN B 72LEU B 75 | 1.62A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.47A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.48A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU C 93ALA C 39GLY C 79ASN C 72LEU C 75 | 1.60A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.69A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.47A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 75VAL C 96ALA C 39VAL C 36LEU C 93 | 1.60A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.64A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.75A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124VAL C 36LEU C 127 | 1.42A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.51A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.70A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 75VAL E 96ALA E 39VAL E 36LEU E 93 | 1.59A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU E 153VAL E 151ALA E 124VAL E 95VAL E 36LEU E 127 | 1.44A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 123VAL E 35ALA E 27ASN E 54ALA E 56 | 1.66A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.54A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 36LEU B 109LEU B 153CYH B 143 | 1.56A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.69A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.74A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.48A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124LEU D 127ALA D 112 | 1.50A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.74A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.52A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 75VAL B 96ALA B 39VAL B 36LEU B 93 | 1.61A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 142PHE B 116LEU B 126ALA B 129ASP B 135 | 1.75A | NoneNoneAPR B 201 (-4.7A)APR B 201 (-3.6A)None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 123VAL D 35ALA D 27ASN D 54ALA D 56 | 1.75A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU D 153VAL D 151ALA D 124VAL D 95VAL D 36LEU D 127 | 1.48A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 36LEU C 109LEU C 153CYH C 143 | 1.54A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 153VAL D 151ALA D 124VAL D 36LEU D 127 | 1.48A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU C 153VAL C 151ALA C 124VAL C 95VAL C 36LEU C 127 | 1.43A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU D 93ALA D 39GLY D 79ASN D 72LEU D 75 | 1.64A | NoneNoneEDO D 203 (-3.1A)NoneEDO D 202 (-4.6A) | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL C 142PHE C 116LEU C 126ALA C 129ASP C 135 | 1.75A | NoneNoneAPR C 201 (-4.8A)APR C 201 (-3.6A)None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124LEU E 127ALA E 112 | 1.45A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 123VAL E 36LEU E 109LEU E 153CYH E 143 | 1.55A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 153VAL E 151ALA E 124LEU E 127ALA E 112 | 1.46A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.45A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.47A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.55A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 96ALA A 39VAL A 36LEU A 93 | 1.53A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU B 93ALA B 39GLY B 79ASN B 72LEU B 75 | 1.62A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 36LEU A 109LEU A 153CYH A 143 | 1.58A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU A 93ALA A 39GLY A 79ASN A 72LEU A 75 | 1.62A | NoneNoneEDO A 204 (-3.6A)NoneNone | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.72A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU B 153VAL B 151ALA B 124VAL B 95VAL B 36LEU B 127 | 1.40A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.70A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 35ALA C 27ASN C 54ALA C 56 | 1.75A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124VAL A 36LEU A 127 | 1.45A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | LEU C 93ALA C 39GLY C 79ASN C 72LEU C 75 | 1.64A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124VAL C 36LEU C 127 | 1.43A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124VAL B 36LEU B 127 | 1.41A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 153VAL C 151ALA C 124LEU C 127ALA C 112 | 1.50A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 75VAL B 96ALA B 39VAL B 36LEU B 93 | 1.52A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 153VAL A 151ALA A 124LEU A 127ALA A 112 | 1.52A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.71A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | TYR B 113VAL B 147PHE B 168LEU B 153ALA B 124 | 1.74A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 123VAL B 35ALA B 27ASN B 54ALA B 56 | 1.66A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU C 153VAL C 151ALA C 124VAL C 95VAL C 36LEU C 127 | 1.42A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 93VAL C 82GLY C 79ASN C 72LEU C 75 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 153VAL B 151ALA B 124LEU B 127ALA B 112 | 1.49A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 6 / 12 | LEU A 153VAL A 151ALA A 124VAL A 95VAL A 36LEU A 127 | 1.45A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 123VAL A 35ALA A 27ASN A 54ALA A 56 | 1.73A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 123VAL C 36LEU C 109LEU C 153CYH C 143 | 1.57A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 93VAL A 82GLY A 79ASN A 72LEU A 75 | 1.72A | NoneNoneEDO A 204 (-3.6A)NoneNone | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 11 | MET A 264ASN A 203LEU A 205ALA A 206PHE A 294 | 1.40A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 202VAL A 296PHE A 294GLY A 251LEU A 253 | 1.63A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.61A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171ALA A 173PHE A 185GLY A 195 | 1.74A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171GLU A 290PHE A 185GLY A 195 | 1.66A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.62A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.53A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.51A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.50A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.49A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423GLY A 841LEU A 838PHE A 881 | 1.75A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 11 | LEU B 98ALA A 379LEU B 91ALA A 375PHE A 504 | 1.78A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883TYR A 884VAL A 880PHE A 429GLY A 841 | 1.71A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862VAL A 844VAL A 848GLY A 839PHE A 419 | 1.64A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 688THR A 687LEU A 638ALA A 634PHE A 694 | 1.68A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.50A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.62A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.45A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP8 (SARS-CoV-2) | 5 / 12 | ILE D 172LEU D 128ALA D 188LEU D 169CYH D 142 | 1.56A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 327 | 1.43A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423PHE A 429GLY A 839PHE A 881 | 1.68A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.50A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.44A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.46A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.60A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 345 | 1.36A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 838PHE A 428LEU A 869ALA A 866ASP A 865 | 1.69A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 11 | LEU C 28THR A 409ASN C 37LEU C 14ALA A 443 | 1.78A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.65A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 32VAL A 31THR A 141ALA A 34PHE A 35 | 1.76A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 688THR A 687LEU A 638ALA A 634PHE A 694 | 1.74A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LYS C 2MET C 52ASN D 104LEU D 103ASP D 99 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.65A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 157LEU A 115VAL A 148LEU A 32CYH A 16 | 1.49A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 67VAL A 36VAL A 18LEU A 89CYH A 38 | 1.49A | NoneNoneDMS A 403 ( 4.9A)NoneNone | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 77VAL A 35LEU A 87CYH A 38PHE A 66 | 1.64A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 11 | LEU A 227MET A 264ASN A 203LEU A 205ALA A 206 | 1.51A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205VAL A 202PHE A 230LEU A 227ASP A 245 | 1.65A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171GLU A 290PHE A 185GLY A 195 | 1.66A | DMS A 405 ( 4.9A)NoneNoneNoneNone | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.41A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883TYR A 884VAL A 880PHE A 429GLY A 841 | 1.68A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 688THR A 687LEU A 638ALA A 634PHE A 694 | 1.69A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.48A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862VAL A 844VAL A 848GLY A 839PHE A 419 | 1.66A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.45A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ALA A 423VAL A 880PHE A 429GLY A 839PHE A 859 | 1.66A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ALA A 379LEU B 103VAL A 341GLY A 345CYH B 114 | 1.55A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | VAL B 115THR B 123ASN B 104LEU B 103ALA B 102 | 1.74A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 345 | 1.32A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 103VAL C 16VAL C 12LEU C 59PHE D 92 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535GLU A 658GLY A 352LEU A 351PHE A 652 | 1.51A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 11 | LEU C 28THR A 409ASN C 37LEU C 14ALA A 443 | 1.79A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 327 | 1.35A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883TYR A 884VAL A 880PHE A 429GLY A 841 | 1.66A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 11 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.48A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 838PHE A 428LEU A 869ALA A 866ASP A 865 | 1.72A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 95VAL C 16VAL C 12LEU C 59PHE D 92 | 1.42A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535GLU A 658GLY A 352LEU A 351PHE A 652 | 1.54A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.51A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.66A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423PHE A 429GLY A 839PHE A 881 | 1.65A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.58A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.56A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.56A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ILE A 696VAL A 785LEU A 749VAL A 704CYH A 697 | 1.55A | None | |||
![]() | 4WA9_A_AXIA9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 11 | LEU B 98ALA A 379LEU B 91ALA A 375PHE A 504 | 1.79A | None | |||
![]() | 4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535GLU A 658GLY A 352LEU A 351PHE A 652 | 1.56A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 327 | 1.44A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 186VAL A 182ALA A 185LEU A 207ALA A 125 | 1.62A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.68A | None | |||
![]() | 4TWP_A_AXIA601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 33ALA A 443PHE A 442ASN A 447ALA A 448 | 1.53A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 106ALA A 379LEU B 103VAL A 341GLY A 345 | 1.35A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535GLU A 658GLY A 352LEU A 351PHE A 652 | 1.54A | None | |||
![]() | 4WA9_B_AXIB9000_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | TYR A 884ALA A 423GLY A 839LEU A 838PHE A 881 | 1.52A | None | |||
![]() | 4TWP_B_AXIB601_1 (TYROSINE-PROTEINKINASE ABL1) | 7bv2 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | LEU C 14VAL C 33ALA A 443LEU C 40ASP C 38 | 1.61A | None | |||
![]() | 4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIALGROWTH FACTORRECEPTOR 2) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 535ALA A 660GLY A 352LEU A 351PHE A 652 | 1.48A | None |